Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

By P. Burge, P. Calverley, P. Jones, S. Spencer, Julie A. Anderson, TK Maslen. British medical journal, 2000

1,745 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/6a3051b6126978efeb83cf413f3535e2cd05dd0f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. D. Parums
2. P. Barnes
3. J. Wedzicha
4. P. Calverley
5. T. Seemungal
6. Bartolome Celli
7. Jorgen Vestbo
8. R. Stockley

In Sociology and Political Science

1. D. Parums
2. P. Barnes
3. P. Calverley
4. R. Stockley
5. J. Wedzicha
6. T. Seemungal
7. G. Hagan
8. Z. Ansari

Citations in the corpus

• Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. (2004, result): “In this study of 1,099 exacerbations recorded on diary cards, only 658 were reported to a physician for treatment, and these rates are in keeping with published clinical trials ( 13 ).”
• Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium (2002, background): “The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study suggested that inhaled steroids might be effective in reducing exacerbations [26].”
• Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. (2015, neutral): “>2 15 (9) 55 (4) 29 (16) 53 (3) 55 (38) 90 (7)”
• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, positive): “Плановая терапия ингаляционными ГКС не оказывает влияния на постепенное снижение ОФВ1 и не снижает общую смертность пациентов с ХОБЛ [126, 175, 176, 195, 246, 247, 520] (уровень доказательности А).”
• The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. (2008, background): “Exacerbations are intermittent events, however, and not all patients experience an exacerbation even during a 3-year trial ( 14 ).”
• Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society (2011, background): “As reported in the 2007 guideline, potential adverse reactions include oropharyngeal candidiasis, dysphonia, and moderate to severe easy bruisability with inhaled corticosteroids (24, 26, 41); dry mouth with tiotropium (42); and increased cardiovascular events with long-acting inhaled -agonists (43)”